Cancer treatment entered a new era when it advanced from a time of treatment regimens based only on chemotherapy to targeted therapies developed from an increasing knowledge of pathogenetic mechanisms involved in the biologic characteristics of tumors. This usually translates into increasing therapeutic power, higher rates of activity, better rates of survival, and fewer or different adverse effects compared with conventional treatments. Newly available therapies are essentially divided into 2 classes: monoclonal antibodies and small molecules, or tyrosine kinase inhibitors.
Montella L, Palmieri G, Lacouture M. The Era of Targeted Therapies: Increasing Role for Novel Oncologic Drugs in Dermatology. Arch Dermatol. 2007;143(6):788–789. doi:10.1001/archderm.143.6.788
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: